Rhythm Pharmaceuticals, Inc.

NasdaqGM:RYTM Stok Raporu

Piyasa değeri: US$3.2b

Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Rhythm Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 3/4

Rhythm Pharmaceuticals' CEO'su David Meeker, Jul2020 tarihinde atandı, in görev süresi 4.25 yıldır. in toplam yıllık tazminatı $ 7.23M olup, şirket hissesi ve opsiyonları dahil olmak üzere 9.7% maaş ve 90.3% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.29% ine doğrudan sahiptir ve bu hisseler $ 9.15M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.9 yıl ve 5.3 yıldır.

Anahtar bilgiler

David Meeker

İcra Kurulu Başkanı

US$7.2m

Toplam tazminat

CEO maaş yüzdesi9.7%
CEO görev süresi4.3yrs
CEO sahipliği0.3%
Yönetim ortalama görev süresi3.9yrs
Yönetim Kurulu ortalama görev süresi5.3yrs

Son yönetim güncellemeleri

Recent updates

Is Rhythm Pharmaceuticals (NASDAQ:RYTM) Using Debt Sensibly?

Sep 23
Is Rhythm Pharmaceuticals (NASDAQ:RYTM) Using Debt Sensibly?

Rhythm: Upcoming sNDA Label Expansion IMCIVREE Isn't The Only Catalyst On Deck

Sep 22

Rhythm: Pivotal Moment Approaching In Hypothalamic Obesity (Rating Upgrade)

Aug 29

Rhythm: Navigating Imcivree's Potential In Rare Obesity Treatments (Rating Upgrade)

Jun 12

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Just Reported And Analysts Have Been Cutting Their Estimates

May 09
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Just Reported And Analysts Have Been Cutting Their Estimates

Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Shares May Have Run Too Fast Too Soon

May 05
Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Shares May Have Run Too Fast Too Soon

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Released Earnings Last Week And Analysts Lifted Their Price Target To US$57.22

Mar 03
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Released Earnings Last Week And Analysts Lifted Their Price Target To US$57.22

Rhythm Pharmaceuticals: Action Too Specific

Feb 23

Subdued Growth No Barrier To Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Price

Jan 08
Subdued Growth No Barrier To Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Price

We're Hopeful That Rhythm Pharmaceuticals (NASDAQ:RYTM) Will Use Its Cash Wisely

Nov 03
We're Hopeful That Rhythm Pharmaceuticals (NASDAQ:RYTM) Will Use Its Cash Wisely

We're Not Very Worried About Rhythm Pharmaceuticals' (NASDAQ:RYTM) Cash Burn Rate

Jul 23
We're Not Very Worried About Rhythm Pharmaceuticals' (NASDAQ:RYTM) Cash Burn Rate

Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Popularity With Investors Is Under Threat From Overpricing

Jun 17
Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Popularity With Investors Is Under Threat From Overpricing

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Just Reported And Analysts Have Been Cutting Their Estimates

May 05
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Just Reported And Analysts Have Been Cutting Their Estimates

Rhythm Pharmaceuticals (NASDAQ:RYTM) Is In A Good Position To Deliver On Growth Plans

Apr 01
Rhythm Pharmaceuticals (NASDAQ:RYTM) Is In A Good Position To Deliver On Growth Plans

An Intrinsic Calculation For Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Suggests It's 46% Undervalued

Dec 15
An Intrinsic Calculation For Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Suggests It's 46% Undervalued

We Think Rhythm Pharmaceuticals (NASDAQ:RYTM) Needs To Drive Business Growth Carefully

Oct 24
We Think Rhythm Pharmaceuticals (NASDAQ:RYTM) Needs To Drive Business Growth Carefully

Rhythm Pharmaceuticals: Revisiting The Investment Thesis

Oct 10

Rhythm Pharmaceuticals announces $100M stock offering; shares fall 12% after hours

Sep 14

Rhythm Pharma's Imcivree drug gets expanded approval by European Commission for BBS

Sep 06

Industry Analysts Just Made An Incredible Upgrade To Their Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Revenue Forecasts

Aug 08
Industry Analysts Just Made An Incredible Upgrade To Their Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Revenue Forecasts

Rhythm Pharmaceuticals Q2 2022 Earnings Preview

Aug 01

Rhythm Pharma gains as NICE recommends obesity drug

Jul 18

CEO Tazminat Analizi

David Meeker'un ücretlendirmesi Rhythm Pharmaceuticals'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Jun 30 2024n/an/a

-US$261m

Mar 31 2024n/an/a

-US$274m

Dec 31 2023US$7mUS$705k

-US$185m

Sep 30 2023n/an/a

-US$186m

Jun 30 2023n/an/a

-US$182m

Mar 31 2023n/an/a

-US$181m

Dec 31 2022US$3mUS$652k

-US$181m

Sep 30 2022n/an/a

-US$181m

Jun 30 2022n/an/a

-US$176m

Mar 31 2022n/an/a

-US$166m

Dec 31 2021US$6mUS$630k

-US$70m

Sep 30 2021n/an/a

-US$62m

Jun 30 2021n/an/a

-US$60m

Mar 31 2021n/an/a

-US$56m

Dec 31 2020US$15mUS$262k

-US$134m

Sep 30 2020n/an/a

-US$132m

Jun 30 2020n/an/a

-US$134m

Mar 31 2020n/an/a

-US$146m

Dec 31 2019US$287kn/a

-US$141m

Sep 30 2019n/an/a

-US$133m

Jun 30 2019n/an/a

-US$115m

Mar 31 2019n/an/a

-US$87m

Dec 31 2018US$282kn/a

-US$74m

Sep 30 2018n/an/a

-US$59m

Jun 30 2018n/an/a

-US$53m

Mar 31 2018n/an/a

-US$47m

Dec 31 2017US$268kn/a

-US$38m

Tazminat ve Piyasa: David 'ın toplam tazminatı ($USD 7.23M ) US pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 6.79M ).

Tazminat ve Kazançlar: David şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

David Meeker (70 yo)

4.3yrs

Görev süresi

US$7,230,457

Tazminat

Dr. David P. Meeker, M.D., had been Independent Non-Executive Director of Pharvaris N.V. (formerly known as Pharvaris B.V.) since January 1, 2021 and serves as its Independent Non-Executive Chair. Dr. Meek...

Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
David Meeker
Chairman4.3yrsUS$7.23m0.29%
$ 9.0m
Hunter Smith
CFO & Treasurer7.3yrsUS$2.31m0.16%
$ 5.1m
Joseph Shulman
Chief Technical Officer4.3yrsUS$1.74m0.000050%
$ 1.6k
Yann Mazabraud
Executive VP & Head of International4yrsUS$1.74m0.057%
$ 1.8m
Jennifer Lee
Executive VP & Head of North America3.9yrsUS$2.11m0.011%
$ 354.8k
Christopher German
Corporate Controller1.6yrsVeri yok0.0013%
$ 41.1k
Alastair Garfield
Chief Scientific Officerless than a yearVeri yokVeri yok
David Connolly
Head of Investor Relations & Corporate Communicationsno dataVeri yokVeri yok
Jim Flaherty
Senior VP & General Counsel3.9yrsVeri yokVeri yok
Sarah Ryan
Vice President of Sales & Marketingno dataVeri yokVeri yok
Pamela Cramer
Chief Human Resources Officer3.3yrsVeri yok0.022%
$ 698.8k
Elisabeth Cronert-Bendell
Senior VP & Head of Strategy2.7yrsVeri yokVeri yok

3.9yrs

Ortalama Görev Süresi

51yo

Ortalama Yaş

Deneyimli Yönetim: RYTM 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.9 yıldır).

Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
David Meeker
Chairman8.9yrsUS$7.23m0.29%
$ 9.0m
Christopher German
Corporate Controller1.6yrsVeri yok0.0013%
$ 41.1k
Jennifer Good
Independent Director5.3yrsUS$283.77k0.0049%
$ 155.4k
David W. McGirr
Independent Director8.9yrsUS$308.77k0.0049%
$ 155.4k
Edward Mathers
Lead Independent Director11.6yrsUS$328.77k0.014%
$ 454.2k
Lynn Tetrault
Independent Director3.8yrsUS$298.77k0.0049%
$ 155.4k
William Chin
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Elizabeth Stoner
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Michael Camilleri
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Lee Kaplan
Chairman of Scientific Advisory Boardno dataVeri yokVeri yok
John Amatruda
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Stuart Arbuckle
Independent Director5.3yrsUS$301.27k0.0049%
$ 155.4k

5.3yrs

Ortalama Görev Süresi

67yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: RYTM 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.3 yıldır).